PubMed Journals Articles About "Clinical Study Of RhTSH In The Treatment Of Patients With Thyroid Cancer After Resection Of Stage I/II" RSS

13:49 EST 18th January 2020 | BioPortfolio

Clinical Study Of RhTSH In The Treatment Of Patients With Thyroid Cancer After Resection Of Stage I/II PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Clinical Study Of RhTSH In The Treatment Of Patients With Thyroid Cancer After Resection Of Stage I/II articles that have been published worldwide.

More Information about "Clinical Study Of RhTSH In The Treatment Of Patients With Thyroid Cancer After Resection Of Stage I/II" on BioPortfolio

We have published hundreds of Clinical Study Of RhTSH In The Treatment Of Patients With Thyroid Cancer After Resection Of Stage I/II news stories on BioPortfolio along with dozens of Clinical Study Of RhTSH In The Treatment Of Patients With Thyroid Cancer After Resection Of Stage I/II Clinical Trials and PubMed Articles about Clinical Study Of RhTSH In The Treatment Of Patients With Thyroid Cancer After Resection Of Stage I/II for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Clinical Study Of RhTSH In The Treatment Of Patients With Thyroid Cancer After Resection Of Stage I/II Companies in our database. You can also find out about relevant Clinical Study Of RhTSH In The Treatment Of Patients With Thyroid Cancer After Resection Of Stage I/II Drugs and Medications on this site too.

Showing "Clinical Study rhTSH Treatment Patients With Thyroid Cancer" PubMed Articles 1–25 of 110,000+

Acute airway compromise after recombinant human TSH administration: A case report and review of the literature.

Radioiodine ablation is a commonly utilized treatment for differentiated thyroid carcinoma. Uptake of radioiodine can be enhanced by pretreatment with thyroid hormone withdrawal or administration of recombinant human thyroid-stimulating hormone (rhTSH). rhTSH is generally well-tolerated with minimal adverse effects. However, in patients with extensive tumor burden in confined anatomic spaces, rapid enlargement of normal or neoplastic thyroid tissue secondary to rhTSH administration can result in significant...

Thyroid nodules as a risk factor for thyroid cancer in patients with Grave's disease: a systematic review and meta-analysis of observational studies in surgically treated patients.

Graves' disease (GD) is an autoimmune thyroid disorder characterized by hyperthyroidism. The incidence of thyroid cancer in patients with GD varies from 0.15% to 15%. There is conflicting evidence on the role of thyroid nodules as a risk factor for thyroid cancer in patients with GD.

New aspects in thyroid cancer treatment : Highlights of the 2019 ASCO Annual Meeting.

The majority of patients with thyroid cancer have a remarkably good chance of cure in the context of surgical treatment, due to their mostly local tumor spread. However, a small proportion of patients with advanced and metastatic thyroid tumors usually require multimodality treatment. Abstracts from the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting are summarized in this review, to provide insights into current aspects of thyroid carcinoma treatment. In addition to innovations in the tr...

Disease Activity May Not Affect the Prognosis of Coexisting Thyroid Cancer in Acromegalic Patients.

Acromegaly is known to be associated with high incidence of malignancies probably due to the mitogenic effects of IGF-1. Differentiated thyroid cancer (DTC) is reported to be one of the most frequent malignancies associated with acromegaly. But there is no data about the clinical course of DTC in acromegalic patients. In this study, we evaluated the course of DTC in 14 acromegalic patients retrospectively. Fourteen papillary thyroid cancer patients without acromegaly, who were matched with the acromegalic p...

Radioactive iodine in differentiated thyroid cancer: a national database perspective.

Radioactive iodine (RAI) is a key component in the treatment of differentiated thyroid cancer. RAI has been recommended more selectively in recent years as guidelines evolve to reflect risks and utility in certain patient subsets. In this study we sought to evaluate the survival impact of radioactive iodine in specific thyroid cancer subgroups. Nationwide retrospective cohort study of patients using the National Cancer Database (NCDB) from 2004-2012 and Surveillance, Epidemiology, and End Results (SEER) dat...

A Rare Coexistence of Medullary Thyroid Cancer with Graves Disease: A Case Report and Systematic Review of the Literature.

BACKGROUND Graves disease is occasionally associated with thyroid cancer. The most common histological type of thyroid cancer in patients with Graves disease is papillary followed by follicular. Medullary thyroid cancer and Graves disease have been reported simultaneously only in a few cases in the literature. CASE REPORT A case of coexistence of Graves disease and medullary thyroid cancer is described in this report. The patient was diagnosed with Graves disease 8 years ago. Although he had an initial succ...

A Qualitative Analysis of the Preoperative Needs of Patients With Papillary Thyroid Cancer.

Thyroid cancer patients report unmet needs after diagnosis. However, little is known about their specific needs. Therefore, we sought to characterize the needs of patients with thyroid cancer before undergoing surgery.

Expressions of IL-17 and TNF-α in patients with Hashimoto's disease combined with thyroid cancer before and after surgery and their relationship with prognosis.

This study aimed to investigate expressions and clinical significance of IL-17 and TNF-α after surgery in patients with Hashimoto's disease (HD) combined with thyroid cancer (TC).

Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.

Polo-like kinases (PLKs) are pivotal regulators of cell proliferation and cell survival; therefore, PLKs may be potential targets in the treatment of malignancy. The therapeutic effects of volasertib, a PLKs inhibitor for papillary and follicular thyroid cancer (known as well-differentiated thyroid cancer) were evaluated in this study. Volasertib inhibited cell proliferation in two papillary and two follicular thyroid cancer cell lines in a dose-dependent manner. Volasertib treatment reduced cells in S phas...

Development of thyroid carcinoma during treatment with pembrolizumab in a lung cancer patient.

Pembrolizumab, a programmed death 1 (PD-1) inhibitor, has been shown to have clinically significant efficacy in different types of cancer, providing long-term survival benefit for patients with lung cancer. Herein, we report the development of a primary thyroid cancer in a lung cancer patient that was being treated with pembrolizumab. Primary thyroid malignancy (and not only metastatic disease or immunotherapy-induced thyroiditis) should be considered in lung cancer patients being treated with immune checkp...


Acromegaly results from the excessive production of growth hormone and insulin-like growth factor-1. While there is up to a 2-fold increased prevalence of thyroid nodules in patients with acromegaly, the incidence of thyroid cancer in this population varies from 1.6-10.6% in several European studies. The goal of our study was to determine the prevalence of thyroid nodules and thyroid cancer among patients with acromegaly at a large urban academic U.S. medical center. A retrospective chart review was perfor...

Inverse Relationship of BMI to TSH and Risk of Papillary Thyroid Cancer in Surgical Patients.

Obesity and thyroid cancer has increased in recent decades. Thyroid malignancy is linked with elevated thyroid-stimulating hormone (TSH) levels, which may have a positive association with body mass index (BMI). This study examines obesity and TSH level effect on papillary thyroid cancer (PTC) risk in a surgical population.

Dynamic risk assessment in patients with differentiated thyroid cancer.

The stratification of patients with differentiated thyroid cancer based on their initial risk of recurrence, according to specific clinical, histopathological and perioperative data, is an important starting point for tailoring the follow-up during the first 1 to 2 years after initial therapy (surgery with or without radioiodine ablation). However, risk of recurrence re-stratification based on new clinical data that becomes available after considering the response to treatment (dynamic risk assessment) prov...

Trends in thyroid carcinoma among thyroidectomy patients: a 12-year multicenter study.

Thyroid malignancy, the most diagnosed cancer of the endocrine system, represents 2% of all malignancies worldwide. The increasing incidence of thyroid cancer has been linked to the increasing sensitivity of modern diagnostic methods which overdiagnosis small thyroid tumors.

Clinical efficacy of frameless stereotactic radiosurgery in the management of spinal metastases from thyroid carcinoma.

MINI: Study evaluates the efficacy of CyberKnife® (CK) SRS for thyroid spinal metastases (SM). Patients with SMs from thyroid carcinoma that were treated with CK SRS between 2003 and 2013were identified. CK can be safely used to treat SMs from thyroid cancer with a high rate of local control.

From Overdiagnosis to Overtreatment of Low-risk Thyroid Cancer: A Thematic Analysis of Attitudes and Beliefs of Endocrinologists, Surgeons, and Patients.

The optimal management for patients with small, low-risk thyroid cancer is often debated. We aimed to characterize the attitudes and beliefs of providers and patients about management of small, low-risk thyroid cancer and how they relate to overtreatment.

Low-Risk Thyroid Cancer in Elderly: Total Thyroidectomy/RAI Predominates but Lacks Survival Advantage.

Papillary thyroid cancer (PTC) is the fastest increasing cancer in the United States; incidence increases with age. It generally has a favorable prognosis but may behave more aggressively in older patients. This study aims to describe national treatment patterns for low-risk PTC in older adults.

Investigating the effect of thyroid nodule location on the risk of thyroid cancer.

Thyroid nodules are routinely evaluated with ultrasound. Our aim was to determine if thyroid nodule location was a useful feature to predict thyroid cancer Methods: Retrospective review of patients with thyroid nodules from six referral centers during 2006 to 2010. A total of 3313 adult patients included with thyroid nodules and confirmed benign or malignant thyroid diagnoses Results: Mean patient age was 54.2 (18-97) years, women (n= 2635, 79.8%). A total of 3241 nodules were analyzed, 335 (10.3%) of which...

Increased Incidental Thyroid Cancer in Patients With Subclinical Chronic Lymphocytic Thyroiditis.

The autoimmune process and increased TSH associated with chronic lymphocytic thyroiditis (CLT) are factors that may promote development of thyroid cancer. When surgically removed, the cellular changes of CLT are commonly seen surrounding thyroid cancers. This study investigates the malignancy rate in CLT patients when compared with non-CLT patients after thyroidectomy.

Mebendazole inhibits tumor growth and prevents lung metastasis in models of advanced thyroid cancer.

The most common thyroid malignancy is papillary thyroid cancer. While a majority respond to therapy and have a favorable prognosis, some papillary thyroid cancers persist. This subset may dedifferentiate to anaplastic thyroid cancer, an aggressive, highly invasive and rapidly fatal cancer. Thyroid cancer patients at risk for disease progression and metastasis need earlier, safer and more effective therapies. The purpose of this translational study was to determine if mebendazole could be repurposed to effec...

Concordance in postsurgical radioactive iodine therapy recommendations between Watson for Oncology and clinical practice in patients with differentiated thyroid carcinoma.

To the authors' knowledge, the indications for radioactive iodine (RAI) therapy in patients with differentiated thyroid carcinoma (DTC) are unclear; treatment decisions are based on physician judgment. The objective of the current study was to identify the degree of concordance between postsurgical RAI therapy recommended by Watson for Oncology (WFO), a clinical decision support system for oncological therapy, and that recommended by physicians for patients with DTC.

Obesity and Risk of Differentiated Thyroid Cancer: A Large-Scale Case-Control Study.

Recently, the incidence of thyroid cancer as well as obesity has dramatically increased worldwide. Whether obesity contributes to the development of differentiated thyroid cancer (DTC) remains controversial. We evaluated the relationship between anthropometric measurements and DTC risk.

High Rates of Underlying Thyroid Cancer in Patients Undergoing Thyroidectomy for Hyperthyroidism.

The rate of thyroid cancer in patients with hyperthyroidism is reported to be rare, and patients with toxic thyroid nodules do not routinely undergo fine-needle aspiration (FNA) to evaluate for malignancy. However, higher rates of malignancy in hyperthyroid patients may exist than previously reported. This study examines the rate of malignancy in patients with hyperthyroidism who have undergone thyroidectomy.

MicroRNA-15 regulates the proliferation, migration and invasion of thyroid cancer cells by targeting Bcl-2.

Thyroid cancer causes significant mortality and 1-1.5% of all the new diagnosed cancers are thyroid cancers. The incidence of thyroid cancer is increasing at an alarming rate and therapeutic targets are lacking. This study was undertaken to investigate the role and therapeutic implications of microRNA (miR)-15 in thyroid cancer.

Variations in radioiodine ablation: decision-making after total thyroidectomy.

The role of radioiodine treatment following total thyroidectomy for differentiated thyroid cancer is changing. The last major revision of the American Thyroid Association (ATA) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer in 2015 changed treatment recommendations dramatically in comparison with the European Association of Nuclear Medicine (EANM) 2008 guidelines. We hypothesised that there is marked variability between the different treatment regimens used today.

Quick Search